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Abstract
The origin, range, and structure of prions causing the most common human prion disease, sporadic Creutzfeldt-Jakob
disease (sCJD), are largely unknown. To investigate the molecular mechanism responsible for the broad phenotypic
variability of sCJD, we analyzed the conformational characteristics of protease-sensitive and protease-resistant fractions of
the pathogenic prion protein (PrP
Sc) using novel conformational methods derived from a conformation-dependent
immunoassay (CDI). In 46 brains of patients homozygous for polymorphisms in the PRNP gene and exhibiting either Type 1
or Type 2 western blot pattern of the PrP
Sc, we identified an extensive array of PrP
Sc structures that differ in protease
sensitivity, display of critical domains, and conformational stability. Surprisingly, in sCJD cases homozygous for methionine
or valine at codon 129 of the PRNP gene, the concentration and stability of protease-sensitive conformers of PrP
Sc
correlated with progression rate of the disease. These data indicate that sCJD brains exhibit a wide spectrum of PrP
Sc
structural states, and accordingly argue for a broad spectrum of prion strains coding for different phenotypes. The link
between disease duration, levels, and stability of protease-sensitive conformers of PrP
Sc suggests that these conformers play
an important role in the pathogenesis of sCJD.
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Introduction
Prions cause a group of fatal and rapidly progressing
neurodegenerative diseases, originally described as transmissible
spongiform encephalopathies (TSEs) [1,2]. The most common of
these diseases is sporadic Creutzfeldt-Jakob disease (sCJD), which
accounts for ,85% of all CJD cases worldwide [3]. Although 40
years ago sCJD was shown to be transmissible to nonhuman
primates [4], its pathogenesis remains enigmatic.
Most researchers today believe that all prion diseases are caused
by the accumulation of an aberrantly folded isoform, termed
PrP
Sc, of the prion protein PrP [5]. Having a basic amino acid
composition and an unstructured N-terminus, PrP can assume at
least two conformations: (1) native, a-helix–rich PrP
C and (2)
disease-causing, b-sheet–rich PrP
Sc [6–8]. The latter represents a
misfolded isoform of the normal cellular prion protein PrP
C, which
is host-encoded by the chromosomal gene PRNP and expressed at
different levels in mammalian cells [9]. Yet despite the impressive
progress that has been made in understanding the molecular basis
of prion diseases, the molecular mechanism of initial misfolding
and the high-fidelity replication of the pathogenic conformation of
PrP
Sc in vivo both remain elusive [2,10–12].
Many lines of evidence from experiments with laboratory prion
strains support the view that the phenotype of the disease—its
distinctive incubation time, clinical features, and brain pathol-
ogy—is enciphered in the strain-specific conformation of PrP
Sc
[13–17]. Although remarkable progress has been made in
understanding the structure of laboratory strains of rodent prions
[2,10,18–20], knowledge of the molecular basis of human prion
diseases has lagged behind. Researchers generally agree that the
genotype at codon 129 of the chromosomal gene PRNP underlies
susceptibility to these diseases and, to some degree, their
phenotype [21]. However, in contrast to the experiments with
laboratory rodent prion strains, in which the digestion of brain
PrP
Sc with proteolytic enzyme proteinase K (PK) consistently
results in a single protease-resistant domain with mass ,19 kDa,
the outcome in sCJD is more complex. Distinctive glycosylation
patterns and up to four PK-resistant fragments of the pathogenic
prion protein (rPrP
Sc) found in sCJD brains are easily distinguish-
able on western blot (WB) [14,21–25]. The WB findings together
with PRNP gene polymorphism led Parchi, Gambetti, and
colleagues to posit a clinicopathological classification of sCJD into
five or six subtypes; notably, the WB characteristics of PrP
Sc breed
true upon transmission to susceptible transgenic mice [14,21,22].
An alternative classification of the PrP
Sc types and their pairing
with CJD phenotypes has been proposed by Collinge and
collaborators [23,24,26,27]. This classification differs from the
previous one in two major aspects: First, it recognizes three (not
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Sc electrophoretic mobilities; and second, it identifies also
PrP
Sc isoforms with different ratios of the three PrP glycoforms
[26]. Although the disease phenotypes of patients with sCJD are
remarkably heterogeneous, 21 kDa fragments of unglycosylated
PrP
Sc (Type 1) frequently differ from the phenotypes associated
with the 19 kDa fragments of unglycosylated PrP
Sc (Type 2)
[14,21,22,28].
Cumulatively these findings argue that the PrP
Sc type represents
yet an additional major modifier in human prion diseases;
accordingly, WB-based clinicopathologic classifications became
an important tool in studies of prion pathogenesis in human brains
and in transgenic mice models [14,26]. Now, inasmuch as two
distinct PK cleavage sites in PrP
Sc Types 1 and 2 most likely stem
from distinct conformations, some investigators contend that PrP
Sc
Types 1 and 2 code distinct prion strains [14,23,28,29]. However,
the heterogeneity of sCJD, along with a growing number of studies
including bioassays, all suggest that the range of prions causing
sCJD exceeds the number of categories recognized within the
current WB-based clinicopathologic schemes [30–32]. Addition-
ally, recent findings revealed the co-occurrence of PrP
Sc Types 1
and 2 in up to 44% of sCJD cases and thus created a conundrum
[33–38]. Finally, up to 90% of brain PrP
Sc in sCJD eludes WB
analysis because it is destroyed by proteinase-K treatment, which
is necessary to eliminate PrP
C. Consequently, the conformation or
role of this major protease-sensitive (s) fraction of PrP
Sc in the
pathogenesis of the disease is a subject of speculation [30,39,40].
Aiming to advance our understanding of the molecular
pathogenesis of human prion diseases, we used the conforma-
tion-dependent immunoassay (CDI) [15,30,41] to determine the
conformational range and strain-dependent molecular features of
sCJD PrP
Sc in patients who were homozygous for codon 129 of the
PRNP gene. Even relatively minute variations in a soluble protein
structure can be determined by measuring conformational stability
in a denaturant such as Gdn HCl [42]. Utilizing this concept, we
designed a procedure in which PrP
Sc is first exposed to denaturant
Gdn HCl and then exposed to europium-labeled mAb against the
epitopes hidden in the native conformation [15]. As the
concentration of Gdn HCl increases, PrPSc dissociates and
unfolds from native b-sheet-structured aggregates; and more
epitopes become available to antibody binding. These experiments
involve insoluble oligomeric forms of PrPSc, and denaturation of
this protein is irreversible in vitro; consequently the Gibbs free
energy change (DG) of PrP
Sc cannot be calculated [43]. Therefore
we chose instead to use the Gdn HCl value found at the half-
maximal denaturation ([GdnHCl]1/2) as a measure of the relative
conformational stability of PrPSc. The differences in stability
reveal evidence of distinct conformations of PrP
Sc [15,42,43].
Because CDI is not dependent on protease treatment, it allowed us
to address fundamental questions concerning the concentration
and conformation of different isoforms of sCJD PrPSc, including
protease-sensitive (s) and protease-resistant (r) PrPSc. We found a
broad spectrum of structures that are likely responsible for the
phenotypic heterogeneity of sCJD and we identified the structural
characteristics of PrP
Sc that are linked to the duration of the
disease.
Results
Diagnostic classification of sCJD patients homozygous
for PRNP codon 129 and disease duration
From 340 patients with an unequivocally definite diagnosis of
Type 1 or Type 2 sCJD and who were homozygous for codon 129
polymorphism in the PRNP gene, we selected samples from 46
patients. The descriptive statistics and Kaplan-Meier survival
curves indicate that these cases are representative of the whole
group collected at NPDPSC and are similar to those previously
reported by us and others (Compare Figure 1 and Figure S1,
Table 1) [21,38,44]. As expected, we did not observe statistically
significant differences in sex ratio or age at onset of the disease
[21,44]. Kaplan-Meier analyses of survival (Figure 1) demon-
strated that patients with PrP
Sc Type 1 had a significantly shorter
disease duration than patients with PrP
Sc Type 2 (P=0.002)
despite identical codon 129 MM polymorphism, age, and sex
distribution (Table 1). Moreover, there is an apparent tendency
toward longer survival of patients with Type 2 rPrP
Sc(129 V) than
patients with Type 1 rPrP
Sc(129 M) (P=0.017). The difference in
survival between patients with Type 2 rPrP
Sc(129 V) and Type 2
rPrP
Sc(129 M) was also significant (P=0.008) with shorter survival
of those homozygous for valine (Figure 1).
To ensure that the brain homogenate analyzed by CDI
contained only Type 1 or 2 rPrP
Sc, each brain homogenate
underwent a second WB (Figure S2). The results confirmed the
original diagnostic classification but we found two atypical
patterns: Case #833 (Type 2 PrP
Sc(129 M) and Case #162
(Type 2 PrP
Sc(129 V) revealed, in addition to a band of
unglycosylated rPrP
Sc with apparent molecular mass ,19 kDa,
a second band with electrophoretic mobility corresponding to
mass ,17 kDa. The observation of different glycoform patterns of
PrP
Sc in different sCJD cases before protease K treatment and
distinct resistance to proteolytic degradation of different glyco-
forms of PrP
Sc is interesting and deserves further investigation.
Measurement of PrP
Sc, sPrP
Sc, and rPrP
Sc in sCJD cortex
by CDI
To measure the concentration of different forms of PrP
Sc in the
frontal cortex, we used europium-labeled mAb 3F4 [45] for
detection and 8H4 mAb (epitope residues 175–185) [46] to
capture human PrP
Sc in a sandwich CDI format (Figure S4)
[30,47]. The analytical sensitivity and specificity of the optimized
CDI for detection of both protease-sensitive (s) and protease-
resistant (r) conformers of PrP
Sc was previously reported by us and
others in numerous publications [15,30,41,48–50] and has been
Author Summary
Sporadic Creutzfeldt-Jakob disease (sCJD) is the most
common human prion disease worldwide. This neurode-
generative disease, which is transmissible and invariably
fatal, is characterized by the accumulation of an abnor-
mally folded isoform (PrP
Sc) of a host-encoded protein
(PrP
C), predominantly in the brain. Most researchers
believe that PrP
Sc is the infectious agent and five or six
subtypes of sCJD have been identified. Whether or not
these subtypes represent distinct strains of sCJD prions is
debated in the context of the extraordinary variability of
sCJD phenotypes, frequent co-occurrence of different
PrP
Sc fragments in the same brain, and the fact that up
to 90% of protease-sensitive PrP
Sc eludes the conventional
analysis because it is destroyed by protease treatment.
Using novel conformational methods, we identified within
each clinical and pathological category an array of PrP
Sc
structures that differ in protease-sensitivity, display of
critical domains, and conformational stability. Each of
these features offers evidence of a distinct conformation.
The link between the rate at which the disease progresses,
on the one hand, and the concentration and stability of
protease-sensitive conformers of PrP
Sc on the other,
suggests that these conformers play an important role in
how the disease originates and progresses.
Conformations of PrPSc in Sporadic CJD
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Sc. This
sensitivity of CDI is similar to the sensitivity of human prion
bioassay in Tg(MHu2M)5378/Prnp
0/0 mice [30].
First, we determined the concentration of disease-causing PrP
Sc
in subpopulations of sporadic sCJD patients (Table 1 and
Figure 2). We observed wide interindividual variations, and
approximately sixfold more accumulated PrP
Sc in the frontal
cortex of patients with Type 2 PrP
Sc(129 M) than those with Type
1 PrP
Sc(129 M) or Type 2 PrP
Sc(129 V). A large portion of PrP
Sc
in all groups is protease-sensitive, constituting a pool of sPrP
Sc
conformers (Table 1 and Figure 3a). The digestion with
proteinase K (PK) was performed with 3 IU/ml (100 mg/ml) of
10% brain homogenate containing 1% sarkosyl for one hour at
37uC. The protocol for PrP
Sc digestion, validated in previously
published experiments, was selected according to the following
criteria: 1) complete digestion of PrP
C determined with CDI in
control samples; 2) complete shift of the bands of PrP
Sc to PrP 27–
30 on WBs; 3) unequivocal WB differentiation of Type 1 and Type
2 rPrP
Sc in all tested samples [15,30,38,40,47,51]. Additionally,
the complete digestion of the PrP
Sc N-terminus with PK was
monitored on WBs in all samples (Figure S2).
In patients with Type 2 PrP
Sc(129 M), significantly higher
concentrations of total PrP
Sc and sPrP
Sc protein (Table 1) are
associated with extended duration of disease. However, the
concentration of sPrP
Sc vary greatly between individual patients,
with numerous overlapping values between each classification
group (Figure 3a). Thus, when the concentration of sPrP
Sc is
expressed as a percentage of total PrP
Sc, no significant difference
between groups appears, and the proportion of sPrP
Sc varies from
5% to 90% in individual patients (Figure 3b). We concluded
from these observations that a major portion of pathogenic sCJD
PrP
Sc is protease-sensitive and that the highest levels of sPrP
Sc are
present in Type 2 PrP
Sc(129 M). The observed large interindivid-
ual differences in PK sensitivity likely indicate a broad range of
PrP
Sc conformers within each PRNP genotype and WB pattern
[15,39]. Since the proteolytic sensitivity of PrP
Sc is considered a
reliable and constant marker of a distinct prion strain, the data
support the conclusion that distinct prion structures are present
within each classification group.
Monitoring the exposure of epitopes 108–112 and
175–185 in native sCJD PrP
Sc
The partial exposure of epitopes 108–112 and 175–185 in
native pathogenic PrP
Sc reflects differences in the conformation of
native PrP
Sc [15,52]. When we adopted this approach previously,
we found considerable differences among eight laboratory prion
strains passaged in Syrian hamsters [15]. The denatured state is a
reference corresponding to the concentration of PrP
Sc; the ratio
between the fluorescence signal of europium-labeled mAb 3F4
reacting with PrP
Sc in the native (N) or completely denatured (D)
state represents a relative measure of the degree of exposure of
these epitopes.
The highest D/N PrP
Sc ratio was found in patients with Type 2
PrP
Sc(129 M); and despite a large spread of values, the difference
is statistically significant (P=0.002) (Figure 4). PK treatment
eliminated most of the exposed 108–112 and 175–185 epitopes in
patients with Type 1 PrP
Sc(129 M) and in patients with Type 2
PrP
Sc(129 V), resulting in the increased D/N ratios (Figure 4).
The opposite trend was observed in patients with Type 2
PrP
Sc(129 M). After PK treatment the PK-induced differences
Figure 1. Kaplan-Meier cumulative survival analysis of 46 sCJD cases homozygous for either methionine or valine in codon 129 of
PRNP gene and described in this paper. The sCJD cases carrying pure Type 1 PrP
Sc(129 M) have significantly shorter survival than those with
Type 2 PrP
Sc(129 M) (P=0.002). The difference in survival of sCJD cases with Type 2 PrP
Sc(129 V) is significant compared with Type 1 PrP
Sc(129 M)
(P=0.017) as well as with Type 2 PrP
Sc(129 M) (P=0.008).
doi:10.1371/journal.ppat.1002242.g001
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remarkable degree (P,0.001). Large variations in D/N values
exceed what we expect from our experiments with laboratory
prion strains [15] and suggest that a high degree of conformational
heterogeneity exists in PrP
Sc aggregates. Protease treatment
change the ratio in all groups and reduced the heterogeneity in
MM2 sCJD, and as a result, each group could be reliably
differentiated. The increased frequency of exposed epitopes in
codon 129 MM samples with Type 2 rPrP
Sc after PK treatment is
unexpected and may indicate one of three possibilities: that the
ligand protecting the 3F4 epitope was removed by PK treatment;
that epitope 108–112 was protected by the N-terminus of PrP
Sc;o r
that conformational transition resulted in more exposed 108–112
epitopes. Whether the epitopes hindrance in undigested PrPSc is
the result of lipid, glycosaminoglycan, nucleic acid, or protein
binding to the conformers unique to the MM2 sCJDF PrPSc
remains to be established.
Dissociation and unfolding of sCJD PrP
Sc, sPrP
Sc, and
rPrP
Sc monitored by CDI
First, we asked whether the PTA precipitation has an impact on
the stability of PrP
Sc. This step in the protocol was important for
eliminating high concentrations of PrP
C and for concentrating
PrP
Sc in brain samples with relatively low levels of PrP
Sc.( Figure
S5). The denaturation curves performed on 5% brain homogenate
before PTA precipitation, on PTA pellet and on PTA pellet
washed with an excess of H2O, were superimposable, an effect
which indicated that PTA quantitatively concentrated all PrP
Sc
conformers and did not influence the stability in CDI. This
conclusion accords with numerous previously published data,
including bioassays, which indicate that PTA dose not precipitate
PrP
C and recovers specifically $95% of infectious PrP
Sc in the
pellet, regardless of protease sensitivity or prion strain [15,30,53–
55]. The error of the method does not exceed 5% in monitoring
[Gdn HCl]1/2 values in the same repeatedly measured brain
samples (Figure S5 and Figure S6).
Since the dissociation and unfolding of oligomeric PrP
Sc may be
dependent on protein concentration [42], we first followed the
process with CDI at different dilutions of PrP
Sc (Figure S5). The
resulting overlapping dissociation/unfolding curves of PrP
Sc with
variation in Gdn HCl1/2 values ,3% indicate that in the 10–
250 ng range, the dissociation/unfolding is independent of
concentration and is highly reproducible. Furthermore, to ensure
the same conditions in all dissociation/unfolding experiments, the
PrP
Sc content in all samples was maintained at a constant 50 ng/
ml concentration. As we observed previously with the western blot
technique, the Gdn HCl1/2 values obtained with frontal, temporal,
parietal, and occipital cortex, thalamus, and cerebellum in three
typical sCJD cases were superimposable, indicating that the same
conformers of PrP
Sc are present in different anatomical areas (data
not shown) [38].
Next we examined the frontal cortex of individual sCJD patients
homozygous for methionine or valine at codon 129 of the PRNP
gene. Typical examples of dissociation/unfolding curves are shown
in Figures 5a, 5b, and 5c. Comparing all sCJD cases, we found a
broad range of Gdn HCl1/2 values ranging from 1.3 to 3.5 M
(Figure 6a). Because of the wide spread of values, the difference
between the cases with Type 1 and 2 PrP
Sc(129 M) is only
marginally significant (P=0.040) and there is no statistically
significant difference among other groups. The possible cluster of
Gdn HCl1/2 values at ,3.0 M is discernible in cases with Type 1
PrP
Sc(129 M) (Figure 6a). We concluded from these experiments
that PrP
Sc proteins in different brains of sCJD patients display a vast
range of unique conformations within each classification group.
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We next investigated the conformational impact of the
proteolytic digestion of sPrP
Sc conformers and the loss of N-
terminal residues in rPrP
Sc. The proteolysis of PrP
Sc with PK
resulted in increased conformational stability in Type 1
rPrP
Sc(129 M) and Type 2 rPrP
Sc(129 V) but did not significantly
reduce the range of values (Figure 6a). In contrast, PK treatment
uniformly decreased Gdn HCl1/2 values in Type 2 rPrP
Sc(129 M)
(Figure 6a). The marked drop in this group’s stability is
statistically significant to a high degree (P,0.001). Additionally,
there is a discernible cluster of Type 2 PrP
Sc(129 M) cases at
,2.6 M (Figure 6a). We interpret the data as providing evidence
of a wide range of unique conformations in each subgroup.
Proteolytic treatment selects the conformers having a more stable
core in Type 1 rPrP
Sc(129 M) and Type 2PrP
Sc(129 V). The
opposite effect of PK, as well as decreased stability, was observed
in samples with Type 2 PrP
Sc(129 M). These data suggest that PK
treatment generates a unique set of conformers in Type
2PrP
Sc(129 M), characterized by increased exposure of 108–112
and 175–185 epitopes (Figure 5) and, upon PK treatment,
decreased stability of the core rPrP
Sc(129 M).
To investigate the conformational stability of sPrP
Sc separately
from rPrP
Sc, we subtracted the relative fractional change in
stability of rPrP
Sc after PK treatment from the PrP
Sc values
obtained before PK (Figures 5a, 5b, and 5c). The resulting
differential curves exhibit Gaussian distribution with the peak at
the median stability of sPrP
Sc; the height and integrated peak area
is proportional to the relative fraction of PK-digested conformers.
Overall stability of Type 1 sPrP
Sc is, as expected, lower than that
of rPrP
Sc and we estimate, from these data alone, that sPrP
Sc
conformers constitute 13–72% of the PrP
Sc (Figure 6a). A larger
spread of positive values obtained with Type 2 sPrP
Sc(129 V)
coincides with a generally larger spread of Gdn HCl1/2 values in
this group. In contrast, the negative differential curves for Type 2
sPrP
Sc(129 M) indicate that sPrP
Sc is more stable than rPrP
Sc in
this patient group (Figure 6b). Notably, the only positive value in
this group came from a sample having an atypical 19 and 17 kDa
doublet of unglycosylated rPrP
Sc on WBs (Figure 6b and Figure
S2). Since the stability of sPrP
Sc and of rPrP
Sc reflect different
initial conformation, the observed spread of values suggests a
broad range of unique PrP
Sc conformers within each PRNP
genotype and WB pattern [15,39,56].
To determine whether unifying trends exist, we examined which
PrP
Sc characteristics have an impact on duration of the disease in
individual patients in all groups using regression analysis. In
contrast to analysis of variance (Anova) used to compare MM1,
MM2, and VV2 groups (Table 1), the regression analysis is
testing the relationship between a dependent variable (duration of
the disease) and independent variables (e.g., sPrPSc levels) in
individual patients. From concentrations of PrP
Sc, sPrP
Sc, and
rPrP
Sc, only the levels of sPrP
Sc (Figure S7a) correlated
significantly with longer duration of the disease. The overall
dependency is driven mainly by the higher levels of sPrP
Sc in Type
2 sPrP
Sc(129 M) and longer duration of the disease in this
subgroup (Table 1). Additionally, the measurement of absolute
concentration of sPrP
Sc is clearly a better indicator of this
relationship than the estimate of the relative fraction (percentage)
of sPrP
Sc (Figure 3b). Despite a wide spread of values, this
Figure 2. The concentration of PrP
Sc and rPrP
Sc (PrP 27–30) in 10% homogenate of the frontal cortex of sCJD cases. The PrP
Sc was
measured by CDI in an aliquot of brain homogenate that was precipitated in the presence of a protease inhibitor cocktail with PTA. The rPrP
Sc
concentration was determined in a second aliquot treated with PK at concentration equivalent to 3 IU/ml (100 mg/ml) of 10% brain homogenate for
one hour at 37uC and precipitated with PTA after blocking PK with the protease inhibitor cocktail. Each sample was measured in triplicate and the
concentration was determined by CDI calibrated with recombinant human PrP(23–231) for samples containing full length PrP
Sc and with
recombinant human PrP(90–231) for samples containing rPrP
Sc (PrP 27–30) after PK treatment. The bars are mean 6 SEM for each sCJD group.
doi:10.1371/journal.ppat.1002242.g002
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experiments with eight laboratory strains of prion, that incubation
time, and by extension duration of the disease, is linked to the
higher levels of sPrP
Sc [15].
We then analyzed the conformational characteristics of PrP
Sc.
The stability of rPrP
Sc clearly did not correlate with duration of
the disease in individual cases (Figure 7a). In contrast, the change
in the stability of PrP
Sc upon PK treatment (Figure S7b)o r
relative levels of sPrP
Sc conformers eliminated by PK (Figure 7b)
expressed as a fraction of all conformers, both demonstrated better
correlation with duration of the disease than did any other
parameter in both Type 1 and Type 2 cases. In contrast to simple
measurement of sPrP
Sc concentration, the stability assay per-
formed before and after PK treatment cumulatively determines
Figure 3. Concentration of sPrP
Sc in frontal cortex of sCJD patients. Absolute (a) and relative (b) concentrations of sPrP
Sc in frontal
cortex of sCJD cases. The higher concentrations of Type 2 PrP
Sc(129 M) are statistically significant against both Type 1 PrP
Sc(129 M) (P=0.002) and
Type 2 PrP
Sc(129 V) (P=0.003). Each data point represents a unique patient measured by CDI in triplicate and the concentration of sPrP
Sc in 10% brain
homogenate was calculated from [PrP
Sc] – [rPrP
Sc]; the percentage of sPrP
Sc is expressed over total PrP
Sc. The horizontal line represents mean for each
group.
doi:10.1371/journal.ppat.1002242.g003
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Sc, change in the slope of the
denaturation curve (dissociation/unfolding rate), and relative
levels of the sPrP
Sc conformers in the total PrP
Sc pool. This effect
leads to the clear separation of Type 1 from Type 2 sPrP
Sc(129 M)
cases (Figure 7b). We interpret these findings as evidence of the
differential impact of protease treatment on different conformers,
resulting in either increased or decreased stability of the remaining
rPrP
Sc core (PrP 27–30). Taken together, higher levels of more
stable sPrP
Sc conformers are associated with extended duration of
the disease. Conversely, lower concentrations of unstable sPrP
Sc
correlate with faster progression of the disease.
Discussion
The discovery of heritable polymorphic PK cleavage sites and
glycosylation patterns in PrP
Sc have been used for the initial
diagnostic classifications of sCJD cases. In concert with the codon
129 PRNP haplotype, the different rPrP
Sc types broadly correlate
with distinct disease phenotypes [14,21,27–29,57]. The majority of
sCJD patients are homozygous for methionine at codon 129 of the
PRNP gene; they also accumulate Type 1 rPrP
Sc and present with
so-called classic sCJD, characterized by rapidly progressive
dementia, early myoclonus, visual disturbances including cortical
blindness, disease duration of approximately 4 months, and fine
punctate (synaptic) deposits of PrP
Sc [21,30]. In contrast, patients
with the second most frequent phenotype are homozygous for
valine at codon 129 of the PRNP gene, accumulate Type 2 PrP
Sc
and manifest a different disease course, with early ataxia,
predominant extra-pyramidal symptoms, relatively late-onset
dementia in the extended course of the disease, and large
plaque-like deposits of PrP
Sc [21].
In the increasing number of subsequent sCJD cases which were
examined with more sensitive and specific techniques, investigators
began to recognize the extensive variability of the sCJD phenotypes,
as well as the extreme complexity of brain immunohistochemistry
and western blot patterns of PrP
Sc [25,32,37,38,57–59]. Although
the western blot systems provided early evidence that molecular
characteristics of PrP
Sc are transmissible, evidence regarding the
original conformation of PrP
Sc remains indirect and limited to the
most protease-resistant fractions. Because variable fractions of PrP
Sc
are protease-sensitive, we decided to determine the conformational
characteristics directly, by using CDI. This method allowed us to
compare the conformational features of human PrP
Sc indepen-
dently of proteolytic treatment and in addition provided quantita-
tive data on levels of PrP
Sc, sPrP
Sc, and rPrP
Sc [15,30]. The CDI
techniques represent a major improvement over previously used
semi-quantitative WB-based methods, the finding that has been
independently confirmed by another group [60,61]. The dissocia-
tion and unfolding of PrPSc in a presence of increasing
concentration of Gdn HCl can be described as follows:
[PrP
Sc]nR[sPrP
Sc]nRiPrPRuPrP, where [PrP
Sc]n are native ag-
gregates of PrP
Sc, [sPrP
Sc]n are soluble protease-sensitive oligomers
of PrP
Sc, iPrP is an intermedite, and uPrP is completely unfolded
(denatured) PrP [7,43,62]. The CDI monitors the global transition
from native aggregates to fully denatured monomers of PrPSc. In
contrast, the WB based techniques monitor either the partial
solubilization of PrP
Sc [63] or conversion of rPrPSc to protease-
sensitive conformers [16] after exposure to denaturant. As a result,
the stability data on soluble protease sensitive oligomers and
intermediates of PrPs cannot be obtained with WB techniques and
lead to the markedly underestimated values [60].
Figure 4. The exposure of 3F4 (108–112) and 8H4 (175–185) epitopes in native PrP
Sc. The exposure of the epitopes was measured before
and after PK treatment in sCJD (red spheres) Type 1 PrP
Sc(129 M), (blue squares) Type 2 PrP
Sc(129 M), and (green diamonds) Type 2 PrP
Sc(129 V). The
reactivity of Eu-labeled 3F4 mAb with native (N) and denatured (D) states of proteins was evaluated in a sandwich-formatted CDI and expressed as D/
N ratio. The proteins were denatured with 5 M Gdn HCl at room temperature for 30 min. Each data point represents a unique patient measured by
CDI in triplicate and the horizontal line corresponds to the mean for the whole group.
doi:10.1371/journal.ppat.1002242.g004
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Sc isoforms in the pathogenesis of
sCJD
The sixfold difference in concentrations of PrP
Sc between Type
1 and Type 2 PrP
Sc(129 M) (Figure 2) revealed in the frontal
cortex by means of CDI was surprising, even though some
variability was to be expected due to differences in the
predominantly affected areas in distinct sCJD phenotypes [30].
The average levels of PrP
Sc are up to 100-fold lower than those in
standard laboratory prion models such as Syrian hamsters infected
with Sc237 prions [15]; and together with the up to 100-fold
variability within each phenotypic group, these lower levels of
Figure 5. Impact of protease treatment on dissociation and unfolding of PrP
Sc monitored with CDI. Typical dissociation and unfolding of
(a, circles) Type 1 PrP
Sc(129 M), (b, squares) Type 2 PrP
Sc(129 M), and (c, diamonds) Type 2 PrP
Sc(129 V) followed by CDI before (blue) and after (red)
PK treatment; the differences in Fapp values before and after PK treatments are in triangles (green) The curves are the best fit with sigmoidal
transition model to determine the midpoint of the curve. The differential values are fitted with Gaussian model and the peak maximum corresponds
to the mean stability of sPrP
Sc. The values of apparent fractional change (Fapp) of each sample aliquot are mean 6 SEM obtained from triplicate
measurements.
doi:10.1371/journal.ppat.1002242.g005
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Sc may partially explain why some sCJD cases are difficult to
transmit, and why lower endpoint titers are obtained with human
prions in transgenic mice expressing human PrP
C [14,26,30,64].
As we observed previously, up to 90% of the pathogenic prion
protein was protease-sensitive [30]. In this study, we found the
highest concentrations in Type 2 PrP
Sc(129 M). The broad range
of absolute and relative levels of rPrP
Sc and sPrP
Sc offers evidence
of a broad spectrum of PrP
Sc molecules differing in protease
sensitivity in each group with an identical polymorphism at codon
129 of the PRNP gene and an identical WB pattern (Figure 3).
Moreover, these findings signal the existence of a variety of sCJD
PrP
Sc conformers; and since protease sensitivity is one of the
Figure 6. Summary data on conformational stability of PrP
Sc, rPrP
Sc, and change in stability induced by PK in 46 sCJD cases. The (a)
conformational stability of PrP
Sc before (blue) and after (red) PK digestion and (b) fractional change in stability of PrP
Sc induced by PK conformers in
individual sCJD samples (circles) Type 1 PrP
Sc(129 M), (squares) Type 2 PrP
Sc(129 M), and (diamonds) Type 2 PrP
Sc(129 V). The stability was
determined by CDI and expressed as Gdn HCl1/2 or stability change (D Fapp) induced by PK. Each symbol represents an individual patient measured
in triplicate and the mean level in each group is indicated by the horizontal line.
doi:10.1371/journal.ppat.1002242.g006
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prion strains exist [15,30,31,58,62,65].
Structural heterogeneity and origin of sCJD PrP
Sc
The CJD cases studied in this paper represent 75–90% of all
clinical and pathologic diagnostic categories of sCJD [21]. In order
to allow unequivocal interpretation of the CDI data, we had to
exclude sCJD patients heterozygous for codon 129 polymorphism
in the PRNP gene, even though they represent ,15–20% of sCJD
cases. The CDI cannot differentiate PrP
Sc with codon 129 M from
V in a mixture which is present in sCJD heterozygots, and
therefore we were unable to differentiate the conformational
impact of codon 129 polymorphism. We also excluded the VV1
type of sCJD because of its rarity. This rare form of sCJD
constitutes ,1% of all sCJD cases and we did not collect enough
cases to allow statistical comparison with the other groups [21].
The heterogeneity of PrP
Sc conformations found with CDI
within sCJD patients homozygous for codon 129 plymorphism of
the PRNP gene is remarkable (Table 1 and Figure 6), with a
range corresponding to that of stabilities found in more than ,30
distinct strains of de-novo and natural laboratory rodent prions
studied up to now [15,16,66]. The high sensitivity and
reproducibility of CDI, together with broad inter-individual
variability detected with techniques based on three different
principles—PK sensitivity, epitope exposure, and conformational
stability—all indicate that the intragroup variations did not
originate in the CDI technique but rather reflect differences in
the structure of PrP
Sc in different patients. The intriguing effect of
Figure 7. Duration of sCJD correlate with conformational stability of sPrP
Sc. The relationship between duration of the disease and
conformational stability of (a) rPrP
Sc and (b) fraction of sPrP
Sc conformers in 46 sCJD patients was analyzed by the regression analysis.
doi:10.1371/journal.ppat.1002242.g007
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Sc(129 M) suggests that
the protease-resistant core of Type 2 was profoundly destabilized.
Since sCJD cases with Type 2 PrP
Sc(129 M) have remarkably
extended disease durations, the molecular mechanism underlying
this effect calls for detailed investigation.
Several theories have been proposed to explain the origin of
sCJD. One argues for spontaneous somatic mutations in PRNP;
another, for rare stochastic conformational changes in PrP
C
[26,67]. Yet a third hypothesis holds that low levels of PrP
Sc are
normally present and cleared, but rise to pathogenic levels when
the clearance mechanism fails [40]. Cumulatively, our findings
indicate that sCJD PrP
Sc exhibit extensive conformational
heterogeneity. Whether this heterogeneity originates in a stochas-
tic misfolding process that generates many distinct self-replicating
conformations [26,67] or in a complex process of evolutionary
selection during development of the disease [17] remains to be
established.
Protease-sensitive conformers of PrP
Sc
We discovered this fraction of PrP
Sc while developing a
conformation-dependent immunoassay (CDI), which does not
require proteolytic degradation of ubiquitous PrP
C [15]. Although
the original definition of sPrP
Sc was only operational, considerable
additional data demonstrate that (1) sPrP
Sc replicates in vivo and
in vitro as an invariant and major fraction of PrP
Sc; (2) sPrP
Sc
separates from rPrP
Sc in high speed centrifugation; and (3) the
proteolytic sensitivity of PrP
Sc can reliably differentiate various
prion strains [15,30,31,58,62,65]. Accumulation of sPrP
Sc pre-
cedes protease-resistant product (rPrP
Sc) in prion infection [40,68];
and up to 90% of PrP
Sc accumulating in CJD brains consists of
sPrP
Sc [30]. Thus, the detection by CDI of sPrP
Sc as a disease-
specific marker is widely regarded as a more reliable basis for
diagnosing prion diseases. This improved detection led to the
discovery of a new human prion disorder, variably protease-
sensitive prionopathy (VPSPr) [15,30,39,69,70]. It is noteworthy
that protease-sensitive synthetic prions generated in vitro during
polymerization of recombinant mouse PrP into amyloid fibers
produced upon inoculation into wild mice prions composed
exclusively of sPrP
Sc [66].
In laboratory rodent prion models, we found that levels of
sPrP
Sc varied with the incubation time of the disease [15] but the
molecular mechanism of this link was unknown [15,30,40].
Subsequent experiments with yeast prions indicated that replica-
tion rate may be an inverse function of the stability of misfolded
protein [71]. The hypothesis based on these experiments posits
that the less stable prions replicate faster by exposing more
available sites for growth of the aggregates. Additionally,
experiments with laboratory and synthetic prions in mouse
suggested that the yeast prion principle may apply to mammalian
prions as well. However, these experiments were based entirely on
the correlation of the shorter incubation time of mouse inoculated
with PrP
Sc that on WBs converted to protease-sensitive isoforms at
a lower denaturant concentration, whereas the replication rates of
mammalian prions were never determined [72].
In this paper we determined the conformational features and
stability of human sPrP
Sc in sCJD. The data indicate that the levels
as well as stability are linked to the progression rate of the disease.
Despite the inevitable influence of variable genetic background
and the potential difficulties in evaluating initial symptoms, the
disease progression rate and incubation time jointly represent an
important parameter, which is influenced by replication rate,
propagation, and clearance of prions from the brain [2,40]. The
correlations among the levels of sPrP
Sc, the stability of sPrP
Sc, and
the duration of the disease found in this study all indicate that
sPrP
Sc conformers play an important role in the pathogenesis.
When sPrP
Sc is less stable than rPrP
Sc, the difference in stability
correlates with less accumulated sPrP
Sc and shorter duration of the
disease. Conversely, when sPrP conformers are more stable than
rPrP
Sc, we observe the opposite effect—more accumulated sPrP
Sc
and extended disease duration. It remains to be determined if
these effects represent an outcome of different replication rates and
clearance, or whether they stem from as yet unknown aspects of
the pathogenesis of sCJD.
Materials and Methods
Ethics statement
All procedures were performed under protocols approved by the
Institutional Review Board at Case Western Reserve University.
In all cases, written informed consent for research was obtained
from patient or legal guardian and the material used had
appropriate ethical approval for use in this project. All patient’s
data and samples were coded and handled according to NIH
guidelines to protect patients’ identities.
Patients and clinical evaluations
We selected 46 representative subjects from a group of 340
patients with definitive diagnosis of sCJD. The criteria for
inclusion were (1) availability of clinical diagnosis of CJD
according to WHO criteria [73–75] and clearly determined and
dated initial symptoms upon neurological examination to ascertain
the disease duration; (2) methionine or valine homozygous at
codon 129 of the human prion protein (PrP) gene (PRNP); (3)
unequivocal classification as pure Type 1 or Type 2 sCJD
according to WB pattern; (4) unequivocal classification of
pathology as definite Type 1 or 2 at the National Prion Disease
Pathology Surveillance Center (NPDPSC) in Cleveland, OH; (5)
demographic data distribution within 95% confidence interval of
the whole group resulting in no difference between selected cases
and the whole group in any of the statistically followed parameters.
Retrospective charts review was carried out for all subjects, with
particular attention to the documented initial cardinal clinical
signs of sCJD such as cognitive impairment, ataxia, and myoclonus
[73–75]. We also reviewed the findings on electroencephalogra-
phy, brain magnetic resonance imaging, and CSF markers when
available.
Brain samples and PRNP gene sequencing
All Type 1–2 patients or uncertain cases were excluded from
this study. DNA was extracted from frozen brain tissues in all
cases, and genotypic analysis of the PRNP coding region was
performed as described [29,30,76]. On the basis of diagnostic
pathology, immunohistochemisty, and western blot (WB) exami-
nation of 2 or 3 brain regions (including frontal, occipital and
cerebellum cortices) with mAb 3F4, the pathogenic PrP
Sc was
classified as (1) Type 1 PrP
Sc(129 M) (n=16); (2) Type 2 PrP
Sc
(129 M, n=16); or (3) Type 2 PrP
Sc (129 V, n=14). Patients
lacked pathogenic mutations in the PRNP and had no history of
familial diseases or known exposure to prion agents. These cases
underwent additional detailed WB analyses of the PrP
Sc so that we
could ascertain the accuracy of their original classification and
confirm that the same brain homogenate analyzed by CDI
contained pure Type 1 PrP
Sc(129 M), Type 2 PrP
Sc(129 M), and
Type 2 PrP
Sc(129 V).
Coronal sections of human brain tissues were obtained at
autopsy and stored at 80uC. Three 200–350 mg cuts of frontal
(superior and more posterior middle gyri) cortex were taken from
each brain and used for molecular analyses. The other symmetric
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and immunohistochemical purposes.
Brain homogenates and precipitation of prions with PTA
Slices of tissues weighing 200–350 mg were first homogenized
to a final 15% (w/v) concentration in calcium- and magnesium-
free PBS, pH 7.4, by 3 75 s cycles with Mini-beadbeater 16 Cell
Disrupter (Biospec, Bartlesville, OK). The homogenates were then
diluted to a final 5% (w/v) in 1% (v/v) sarkosyl in PBS, pH 7.4
and rehomogenized. After clarification at 5006g for 5 min., one
aliquot of the supernatant was treated with protease inhibitors
(0.5 mM PMSF and aprotinin and leupeptin at 5 ug/ml,
respectively). The second aliquot was treated with 50 mg/ml of
proteinase K (Amresco, Solon, OH) for 1 h at 37uC shaking
600 rpm on Eppendorf Thermomixer (Eppendorf, Hauppauge,
NY) and PK was blocked with PMSF and aprotinin-leupeptin
cocktail. Both aliquots were precipitated with final 0.32% (v/v)
NaPTA after 1 h incubation at 37uC as described [15]. The
samples were spun 30 min at 14,0006 g in Allegra X-22R
tabletop centrifuge (Beckman Coulter, Brea, CA) and the pellets
were resuspended in 250 ul of deionized water containing protease
inhibitors (0.05 mM PMSF, aprotinin and leupeptin at 1 ug/ml
each, respectively, and stored for analysis at 280uC.
Western blots
Both PK-treated and untreated samples were diluted 9-fold in
16Laemmli Buffer (Bio-Rad, Hercules, CA) containing 5% (v/v)
beta-mercaptoethanol (ME) and final 115 mM Tris-HCl, pH 6.8.
Samples were heated for 5 min at 100uC and ,2 ng of PrP per
lane was loaded onto 1 mm 15% Polyacrylamide Tris-HCl, SDS-
PAGE gels (Bio-Rad) mounted in Bio-Rad Western Blot
apparatus. After electro-transfer to Immobilon-P Transfer Mem-
branes (Millipore, Bedford, MA), the membranes were blocked
with 2% (w/v) BSA in TBS containing 0.1% of Tween 20 (v/v)
and 0.05% (v/v) Kathon CG/ICP (Sigma, St. Louis, MO). The
PVDF membranes were developed with 0.05 ug/ml of biotiny-
lated mAb 3F4 (Covance, Princeton, NJ) followed by 0.0175 ug/
ml Streptavidin-Peroxidase conjugate (Fisher Scientific, Pittsburg,
PA) or with ascitic fluid containing mAb 3F4 (kindly supplied by
Richard Kascsak) diluted 1:20,000 followed by Peroxidase-labeled
sheep anti-mouse IgG Ab (Amersham, Piscataway, NJ) and diluted
1:3000. The membranes were developed with the ECL Plus
detection system (Amersham) and exposed to Kodak BioMax MR
Films (Fisher Scientific) or Kodak BioMax XAR Films (Fisher
Scientific).
Conformation-dependent immunoassay (CDI)
The CDI for human PrP was performed as described previously
[30,47], with several modifications. First, we used white Lumitrac
600 High Binding Plates (E&K Scientific, Santa Clara, CA) coated
with mAb 8H4 (epitope 175–185) [46] in 200 mM NaH2PO4
containing 0.03% (w/v) NaN3, pH 7.5. Second, aliquots of 20 ml
from each fraction containing 0.007% (v/v) of Patent Blue V
(Sigma) were directly loaded into wells of white strip plates
prefilled with 200 ml of Assay Buffer (Perkin Elmer, Waltham,
MA). Finally, the captured PrP was detected by a europium-
conjugated [15] anti-PrP mAb 3F4 (epitope 108–112) [45] and the
time-resolved fluorescence (TRF) signals were measured by the
multi-mode microplate reader PHERAstar Plus (BMG LabTech,
Durham, NC). The recHuPrP(90–231,129 M) and PrP(23–
231,129 M) used as a calibrant in the CDI was a gift from Witold
Surewicz, and preparation and purification have been described
previously [77]. The initial concentration of recombinant human
PrP(23–231) and PreP(90–231) was calculated from absorbance at
280 nm and molar extinction coefficient 56650 M
21 cm
21 and
21640 M
21 cm
21, respectively. The purified recombinant pro-
teins were dissolved in 4 M GdnHCl and 50% Stabilcoat
(SurModics, Eden Prairie, MN), and stored at 280uC. The
concentration of PrP was calculated from the CDI signal of
denatured samples using calibration cure prepared with either
recPrP(23–231) for samples containing full length PrP
Sc or
recPrP(90–231) for samples containing truncated rPrP
Sc (PrP
27–30) after proteinase-K treatment. This separate calibration was
necessary due to the ,3.5-fold lower affinity of mAb 3F4 with full
length hurman PrP(23–231,129 M) compared to PrP(90–
231,129 M) (Figure S3).
Monitoring dissociation and unfolding of PrP
Sc by CDI
The denaturation of human PrP
Sc was performed as described
previously [15], with several modifications. Frozen aliquots of
PrP
Sc were thawed, sonicated 365 s at 60% power with Sonicator
4000 (Qsonica, Newtown, CT), and the concentration was
adjusted to constant ,50 ng/ml of PrP
Sc. The 15 ml aliquots in
15 tubes were treated with increasing concentrations of 8 M
GdnHCl containing 0.007% (v/v) Patent Blue V (Sigma, St. Louis,
MO) in 0.25 M or 0.5 M increments. After 30 min incubation at
room temperature, individual samples were rapidly diluted with
Assay Buffer (Perkin Elmer, Waltham, MA) containing diminish-
ing concentrations of 8 M GdnHCl, so that the final concentration
in all samples was 0.411 M. Each individual aliquot was
immediately loaded in triplicate to dry white Lumitrac 600, High
Binding Plates (E&K Scientific, Santa Clara, CA), coated with
mAb 8H4, and developed in accordance with CDI protocol using
europium-labeled mAb 3F4 for detection [15,30,41,78].
The raw TRF signal was converted into the apparent fractional
change of unfolding (Fapp) as follows: F=(TRFOBS2TRFN)/
(TRFU2TRFN) where TRFOBS is the observed TRF value, and
TRFN and TRFU are the TRF values for native and unfolded
forms, respectively, at the given Gdn HCl concentration [7]. To
determine the concentration of Gdn HCl where 50% of PrP
Sc is
unfolded ([Gdn HCl]1/2), the data were fitted by least square
method with a sigmoideal transition model (Equation 1):
Fapp~F0z
Fmax{F0 ðÞ
1ze
c1=2{c
   .
r
no
The apparent fractional change (F) in the TRF signal is the
function of Gdn HCl concentration(c); c1/2 is the concentration of
Gdn HCl at which 50% of PrP
Sc is dissociated/unfolded and r is
the slope constant. To determine the impact of protease treatment
on the conformational stability of PrP
Sc, the values of fractional
change after PK were subtracted from Fapp values obtained before
PK (DFapp=F
02F
PK) and then fitted with a Gaussian model to
estimate the proportion and average stability of sPrP
Sc conformers
(Equation 2):
DFapp~F0zA
{ c{c0 ðÞ
2   
In this model, the Pk-induced fractional change is DF, F0 is
fractional change at 0 concentration of Gdn HCl, and c0 is the
Gdn HCl concentration at the maximum height A of the peak.
Statistical analysis
We investigated the effect of the following demographic and
laboratory variables on survival: sex; age at onset; duration of the
Conformations of PrPSc in Sporadic CJD
PLoS Pathogens | www.plospathogens.org 12 September 2011 | Volume 7 | Issue 9 | e1002242disease; electrophoretic Type of PrP 27–30; and the concentration
and stability of PrP
Sc in Gdn HCl before and after PK treatment
[15]. Cumulative survival curves were constructed by the Kaplan–
Meier method, both overall and by stratifying for each of the
above variables. For each type of PrP
Sc and PRNP gene
polymorphism, we report descriptive statistics and the overall
survival times stratified for each variable. In the comparison of
different patient groups, P values were calculated using Anova.
Comparisons of survival curves among groups were carried out by
the log rank (Mantel-Cox) and generalized Wilcoxon test. To
evaluate the dependency of disease duration upon the concentra-
tion and stability of PrP
Sc in individual CJD cases, the data were
analyzed by non-linear regression using the logistic function or the
nonlinear models with the best fit. To obtain significance and to
compare the relative importance of each characteristic of PrPSc,
we used ANOVA and F statistics with regression mean square
(MSR) divided by the residual mean square (MSE). All the
statistical analyses were performed using SPSS 17 software (SPSS
Inc., Chicago, IL).
Supporting Information
Figure S1 Kaplan-Meier cumulative survival analysis of 340
sCJD cases homozygous for either methionine (n=288) or valine
(n=52) in codon 129 of PRNP gene from which were selected the
46 cases described in this paper. The sCJD cases carrying pure
type 1 PrP
Sc(129 M) (n=266) have significantly shorter disease
duration than those with type 2 PrPSc(129 M) (n=22, P,0.001).
The intermediate duration of the disease observed in sCJD cases
with type 2 PrP
Sc(129 V) (n=52) is significant compared with type
1 PrP
Sc(129 M) (P,0.001) or type 2 PrP
Sc(129 M) (P,0.001).
(TIF)
Figure S2 Typical WB analysis of PrP
Sc and rPrP
Sc in sCJD
cases. PrP
Sc from 5% brain homogenate in PBS, pH 7.4,
containing 1% Sarcosyl was precipitated with PTA either before
(left lanes) or after (right lanes) digestion with 50 mg/ml of PK at
37uC for 1 h. Note the 19 and 17 kD doublets of unglycosylated
bands of PrP
Sc in MM2 Case #7-927 and VV2 Case #8-848. The
rPrP
Sc bands in Case VV2 9-434 became visible only after
prolonged exposure (data not shown). Internal controls of type 1
(T1) or type 2 (T2) rPrP
Sc(129 M) were incorporated in each WB.
(TIF)
Figure S3 Calibration of CDI with (squares) full length (PrP23–
231, 129 M) or (circles) truncated (PrP90–231, 129 M) prion
protein. The truncated (PrP90–231, 129 M) prion protein corre-
sponds to the human brain PrP 27–30 after proteinase K treatment.
Time-resolved fluorescence (TRF) is reported in counts per minute
(cpm) from triplicate measurement 6 SEM. The initial concentra-
tions of recombinant human PrP(23–231) and PreP(90–231) were
calculated from absorbance at 280 nm and molar extinction
coefficient 56650 M
21 cm
21 and 21640 M
21 cm
21, respectively.
(TIF)
Figure S4 The (a) raw time-resolved fluorescence (TRF) data
and (b) end-point sensitivity in detection of sCJD PrPSc with CDI
before and after proteinase K treatment in different cases of sCJD
and a case of other neurological disorder (OND). To obtain values
for total PrPSc, CDI was performed in an aliquot of brain
homogenate that was precipitated in the presence of a protease
inhibitor cocktail with PTA. To obtain CDI readings for rPrPSc,
samples were treated with PK at concentration equivalent to
3 IU/ml (100 mg/ml) of 10% brain homogenate for one hour at
37uC and precipitated with PTA after blocking PK with the
protease inhibitor cocktail. The 8H4 mAb was used {Zanusso,
1998 #4838} for capture and Eu-labeled 3F4 mAb for detection
under native (N) and denatured (D) conditions {Safar, 2005
#6826;Safar, 2002 #5989;Safar, 1998 #4776}. The (D – N)
values of time-resolved fluorescence (TRF) measured in counts per
minute (cpm) are directly proportional to the concentration of
PrPSc [Safar, 2005 #6826;Safar, 2002 #5989;Safar, 1998
#4776]. Data points and bars represent average 6 standard
deviation (SD) obtained from three or four independent
measurements.
(TIF)
Figure S5 The dissociation and unfolding of PrP
Sc(129 M)
monitored by CDI in 5% brain homogenate (circles), in PTA
pellet (squares), and washed PTA pellet (triangles). The brain
homogenate and PTA precipitation was performed as described in
the Method section. For wash, the PTA pellet was resuspended in
1m lo fH 2O containing protease inhibitors, spun at 14,000 G for
30 min, and then processed as described for the other samples. To
obtain accurate midpoint of the curves from raw TRF data
requires the least square fit of the sigmoideal transition model
(Equation 1).
(TIF)
Figure S6 The dissociation and unfolding of rPrP
Sc monitored
by CDI at different concentrations. The (a) row data with TRF or
(b) values of apparent fractional change (Fapp) at each concentra-
tion of Gdn HCl in each dilution are mean 6 SEM obtained from
triplicateCDImeasurements.Notethe logaritmic scale in the plot A
that was necessary due to the 1000-fold range of TRF values but
made the manuall estimate of the Gdn HCl1/2 difficult. To obtain
accurate midpoint of the curves from raw TRF data, we used the
least square fit of the sigmoideal transition model (Equation 1) or
Fapp transformation. Both methods gave indentical results.
(TIF)
Figure S7 The relationship between duration of the disease and
(a) concentration of sPrPSc or (b) change in the stability of PrP
Sc
after PK digestion in all sCJD patients (n=46). The regression
analysis was performed by using data from (a) Figure 3 and (b)
Figure 6.
(TIF)
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